ASH 2024: Global Updates in the Management of Chronic Lymphocytic Leukemia - Episode 8
Managing CLL with TP53 Mutation or del(17p): Guidelines and Strategies
Panelists review recent ESMO guideline updates for the frontline management of patients with CLL and a TP53 or del(17p) mutation.
Video Player is loading.
Video content above is prompted by the following:
- Briefly review recent ESMO guideline updates for the frontline management of patients with CLL and a TP53 or del(17p) mutation and discuss associated implications. (ESMO CLL Guideline Update 2024)
- How does the presence of TP53 or del(17p) mutations alter your overall treatment approach?
- How does the role of time-limited vs continuous BTKi therapy in the 1L setting differ in this patient population?
- Briefly comment on the underlying rationale and data supporting BTKi therapy as a preferred approach in this setting.
- SEQUOIA – Shadman M, et al. ASH 2024. Abs 3249
- ELEVATE-TN – Sharman JP, et al. ASH 2023. Abs 642
Related Content:
